Merck KGaA Says Outcomes-Based Pact With NHS England 'Precedent-Setting'
Executive Summary
Merck KGaA Healthcare CEO Belén Garijo tells the Pink Sheet that outcomes-based reimbursement deals like the one it has done with NHS England “are the way of the future”.
You may also be interested in...
Merck KGaA Keen To Remain Key Player In MS Now And In Future
The German company is predicting sales in mid-triple-digits in 2019 for Mavenclad, its multiple sclerosis drug which has just been launched in the US, and has highlighted more promising MS data for its BTK inhibitor evobrutinib.
Mavenclad Is Merck KGaA Bright Spot As Q2 Sales Slip
With strong quarterly sales of Mavenclad in Europe, and a recent re-filing of the drug with the FDA, Merck KGaA continues to play the waiting game for top-line growth to return as it banks on the new addition to its MS franchise.
Merck KGaA Highlights Mavenclad Advances In Tough Quarter
Merck KGaA's brace of new products started to garner sales in the third quarter, but the big pharma maintained its 2017 guidance at the lower end of the forecast range in the face of increasing competition to its established pharmaceutical products and to its liquid crystal materials, and currency headwinds.